Acutaas Chemicals (ACUTAAS) Q2 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 25/26 earnings summary
8 Jul, 2026Executive summary
Revenue for Q2 FY26 grew 24.1% year-on-year to INR 306.2 crore (₹3,062 million), driven by advanced pharmaceutical intermediates and stable specialty chemicals performance.
EBITDA for Q2 FY26 increased 94.8% year-on-year to ₹953 million, with PAT up 91.3% to ₹719 million.
The company is building long-term sustainable business across diversified verticals: pharmaceutical, battery chemicals, semiconductors, cosmetics, and specialty chemicals.
Battery chemical business has secured multiple customers globally; production to commence in Q4 FY26 post CapEx completion.
Unaudited standalone and consolidated financial results for Q2 and H1 FY2026 were approved on October 17, 2025, with a limited review by statutory auditors confirming no material misstatements.
Financial highlights
Q2 FY26 revenue: INR 306.2 crore (₹3,062 million), up 24.1% YOY; H1 FY26 revenue: INR 513.4 crore (₹5,134 million), up 21.3% YOY.
Q2 FY26 gross profit: INR 170.7 crore (₹1,707 million), up 59.3% YOY; gross margin expanded to 55.8%-56%.
Q2 FY26 EBITDA: INR 95.3 crore (₹953 million), nearly doubled YOY; EBITDA margin at 31.1%.
Q2 FY26 PAT: INR 71.9 crore (₹719 million), up 91.3% YOY; PAT margin at 23.5%.
Net cash and cash equivalents at INR 240.6 crore as of 30 September 2025.
Cash from operations in H1 FY26: INR 136.5 crore.
Basic and diluted EPS (standalone) for Q2 FY2026 were ₹8.90; for H1 FY2026, ₹14.36.
Outlook and guidance
Revenue growth guidance for FY26 maintained at around 25%.
EBITDA margin guidance revised to 28%-30% for FY26, expected to be sustainable in coming years due to improved product mix and operational efficiency.
Battery chemicals and semiconductor verticals expected to be key growth drivers; electrolyte additive CapEx to be completed by Q4 FY26, with full contribution in FY27.
The company continues to focus on custom synthesis and manufacturing of specialty chemicals for pharmaceutical APIs and related sectors.
Latest events from Acutaas Chemicals
- Q1 FY26 saw 17.3% revenue growth, 199.6% PAT surge, and a new South Korea JV.ACUTAAS
Q1 25/268 Jul 2026 - Q3 FY25 revenue up 65.2% YoY, PAT up 155.1% YoY, and FY25 growth guidance raised to 35%.ACUTAAS
Q3 24/258 Jul 2026 - Global specialty chemicals leader with strong growth, innovation, and sustainability focus.ACUTAAS
Corporate presentation17 May 2026 - Record FY26 growth, margin expansion, South Korea JV, and Rs. 2.5/share dividend recommended.ACUTAAS
Q4 25/2611 May 2026 - Record Q3 revenue, profit, and margins led to upgraded FY26 growth guidance and major JV investment.ACUTAAS
Q3 25/2613 Apr 2026 - Q1 FY25 revenue up 16.6% YoY; margins down, 25% growth guidance and net debt zero achieved.ACUTAAS
Q1 24/2510 Feb 2026 - Q2 FY 2025 revenue up 43.2% YoY, PAT up 155%, and FY 2025 growth guidance raised to 30%.ACUTAAS
Q2 24/2519 Dec 2025 - FY25 revenue surpassed ₹10,000 million, with strong profit growth and 25% growth targeted for FY26.ACUTAAS
Q4 24/2519 Dec 2025